- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bicara Therapeutics Inc (BCAX)
Bicara Therapeutics Inc stock price live, this page displays NASDAQ BCAX stock exchange data. View the BCAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bicara Therapeutics Inc real time stock price chart below.
What Is the Bicara Therapeutics Inc Stock Price Today?
The Bicara Therapeutics Inc stock price today is 23.81.
What Is the Stock Symbol for Bicara Therapeutics Inc?
The stock symbol for Bicara Therapeutics Inc is "BCAX."
What Stock Exchange Does Bicara Therapeutics Inc Trade On?
Bicara Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Bicara Therapeutics Inc a Good Stock to Buy?
Determining whether Bicara Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCAX quote. (ISIN: US0554771032)
What Is the Bicara Therapeutics Inc Stock Price Today?
The Bicara Therapeutics Inc stock price today is 23.81.
What Is the Stock Symbol for Bicara Therapeutics Inc?
The stock symbol for Bicara Therapeutics Inc is "BCAX."
What Stock Exchange Does Bicara Therapeutics Inc Trade On?
Bicara Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Bicara Therapeutics Inc a Good Stock to Buy?
Determining whether Bicara Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCAX quote. (ISIN: US0554771032)
23.81
+0.18(+0.76%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.27
24.97
52 wk Range
10.30
30.99
BCAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.2724.97
52 wk Range
10.3030.99
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCAX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
33.38
Upside
+40.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
11 Buy
3 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.38
(+40.21% Upside)
Bicara Therapeutics Inc Earnings Call Summary for Q2/2026
- Bicara posted Q2 2026 loss of $0.82/share; shares fell 16.7% to $23.11 amid rising expenses and long commercialization timeline concerns.
- Company holds $497M in cash, funding operations into H1 2029; operating expenses to rise through 2026 for trials and commercial prep.
- Lead drug ficerafusp alfa showed durable 3-year survival in head/neck cancer; pivotal FORTIFI-HN01 trial targets mid-2027 interim analysis.
- CEO Claire Mazumdar transitioning to Ryan Cohlhepp in 2027 to lead commercial buildout ahead of potential U.S. approval launch.
- Nine analysts revised earnings down; company faces competition from Genmab/J&J while expanding into colorectal cancer with year-end 2026 data.
Last Updated: 2026-08-11, 09:26 a/m
Read Full TranscriptEarnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.82 / --
Revenue / Forecast
-- / --
Compare BCAX to Peers and Sector
Metrics to compare | BCAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.4x | −2.7x | −0.4x | |
PEG Ratio | 0.26 | −0.04 | 0.00 | |
Price/Book | 3.3x | 3.4x | 2.6x | |
Price / LTM Sales | - | 7.3x | 3.1x | |
Upside (Analyst Target) | 43.9% | 105.3% | 48.4% | |
Fair Value Upside | Unlock | 13.1% | 6.5% | Unlock |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Bicara Therapeutics (BCAX) Stock Price Today?
The Bicara Therapeutics stock price today is 23.81 USD.
What Stock Exchange Does Bicara Therapeutics Trade On?
Bicara Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Bicara Therapeutics?
The stock symbol for Bicara Therapeutics is "BCAX."
What Is the Bicara Therapeutics Market Cap?
As of today, Bicara Therapeutics market cap is 1.56B USD.
What Is Bicara Therapeutics's Earnings Per Share (TTM)?
The Bicara Therapeutics EPS (TTM) is -3.11.
When Is the Next Bicara Therapeutics Earnings Date?
Bicara Therapeutics will release its next earnings report on Aug 11, 2026.
From a Technical Analysis Perspective, Is BCAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Bicara Therapeutics Stock Split?
Bicara Therapeutics has split 0 times.
How Many Employees Does Bicara Therapeutics Have?
Bicara Therapeutics has 103 employees.
What is the current trading status of Bicara Therapeutics (BCAX)?
As of Aug 14, 2026, Bicara Therapeutics (BCAX) is trading at a price of 23.81 USD, with a previous close of 23.63 USD. The stock has fluctuated within a day range of 23.27 USD to 24.97 USD, while its 52-week range spans from 10.30 USD to 30.99 USD.
What Is Bicara Therapeutics (BCAX) Price Target According to Analysts?
The average 12-month price target for Bicara Therapeutics is 33.38 USD, with a high estimate of 45 USD and a low estimate of 20 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.21% Upside potential.
What Is the BCAX Premarket Price?
BCAX's last pre-market stock price is 23.57 USD. The pre-market share volume is 1,620.00, and the stock has decreased by -0.06, or -0.25%.
What Is the BCAX After Hours Price?
BCAX's last after hours stock price is 23.94 USD, the stock has decreased by 0.31, or 1.31%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.